Description
Epilepsy: Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and children aged 3 years and older. Safety and effectiveness for adjunctive therapy in pediatric patients younger than 3 years have not been established (see Epilepsy: Pediatric patients aged 3 to 12 years under Dosage & Administration).
Neuropathic pain: Gabapentin is indicated for the treatment of neuropathic pain which includes diabetic neuropathy, post-herpetic neuralgia and trigeminal neuralgia in adults aged 18 years and older. Safety and effectiveness in patients younger than 18 years have not been established.
General: Gabapentin is given orally with or without food.
When in the judgment of the clinician there is a need for dose reduction, discontinuation, or substitution with an alternative medication, this should be done gradually over a minimum of 1 week.
Epilepsy: Adults and pediatric patients older than 12 years of age: In clinical trials, the effective dosing range was 900 mg/day to 3600 mg/day. Therapy may be initiated by administering 300 mg three times a day on Day 1 or by titrating the dose (Table 2). Thereafter, the dose can be increased in three equally divided doses up to a maximum dose of 3600 mg/day. Doses up to 4800 mg/day have been well tolerated in long-term open-label clinical studies.
